Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cleary

Showing results (421-430 of 445) with videos related to

Pageof 45
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2021
Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal CancerArta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, et al.
Cancer Cell|May 8, 2026
Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancerCourtney T S Kureshi, Michael J Walsh, Rakeeb Kureshi, et al.
Science (New York, N.Y.)|July 11, 2024
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunityMeng-Ju Wu, Hiroshi Kondo, Ashwin V Kammula, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal CancerArta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2026
A Phase 2 Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2Brandon M Huffman, Miklos Diossy, Matthew B Yurgelun, et al.
Journal for Immunotherapy of Cancer|January 25, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.
Medrxiv : the Preprint Server for Health Sciences|April 20, 2026
Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identificationKarl Semaan, Marc Eid, Damien Vasseur, et al.
Nature Cancer|May 25, 2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trialKimberly J Perez, Andressa Dias Costa, Alexander Jordan, et al.
Nature|July 6, 2017
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathwayVasanthi S Viswanathan, Matthew J Ryan, Harshil D Dhruv, et al.
Cancer Discovery|April 30, 2021
<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in CholangiocarcinomaJames M Cleary, Srivatsan Raghavan, Qibiao Wu, et al.
Pageof 45

Showing results (421-430 of 445) with videos related to

Sort By:
Pageof 45
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2021
Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal CancerArta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, et al.
Cancer Cell|May 8, 2026
Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancerCourtney T S Kureshi, Michael J Walsh, Rakeeb Kureshi, et al.
Science (New York, N.Y.)|July 11, 2024
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunityMeng-Ju Wu, Hiroshi Kondo, Ashwin V Kammula, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal CancerArta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2026
A Phase 2 Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2Brandon M Huffman, Miklos Diossy, Matthew B Yurgelun, et al.
Journal for Immunotherapy of Cancer|January 25, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.
Medrxiv : the Preprint Server for Health Sciences|April 20, 2026
Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identificationKarl Semaan, Marc Eid, Damien Vasseur, et al.
Nature Cancer|May 25, 2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trialKimberly J Perez, Andressa Dias Costa, Alexander Jordan, et al.
Nature|July 6, 2017
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathwayVasanthi S Viswanathan, Matthew J Ryan, Harshil D Dhruv, et al.
Cancer Discovery|April 30, 2021
<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in CholangiocarcinomaJames M Cleary, Srivatsan Raghavan, Qibiao Wu, et al.
Pageof 45